Summary
Dr Tricia Tan is a Consultant in Diabetes, Endocrinology and Metabolic Medicine at Imperial College London and NHS Trust. She possesses over 10 years’ experience in gut hormone research and physiological studies into the impact of gut hormones on weight and T2DM. She has completed several Phase I trials on the gut hormone analogues, which are being developed for the treatment of obesity. She is the director of the SAS Gut Hormone service, and her clinical research spans a wide gamut from the diagnosis and treatment of neuroendocrine tumours to diagnostic testing in Endocrine disorders.
Publications
Journals
Kamocka A, McGlone ER, Pérez-Pevida B, et al., 2019, Candy cane revision after Roux-en-Y gastric bypass, Surgical Endoscopy, ISSN:0930-2794
Miras AD, Ravindra S, Humphreys A, et al., 2019, Metabolic Changes and Diabetes Microvascular Complications 5 Years After Obesity Surgery., Obes Surg
Rose F, Bloom S, Tan T, 2019, Novel approaches to anti-obesity drug discovery with gut hormones over the past 10 years., Expert Opin Drug Discov, Pages:1-9
Suliman M, Buckley A, Al Tikriti A, et al., 2019, Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients, Diabetes Obesity & Metabolism, Vol:21, ISSN:1462-8902, Pages:1498-1501
Miras AD, Pérez-Pevida B, Aldhwayan M, et al., 2019, Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial, The Lancet Diabetes & Endocrinology, ISSN:2213-8587